Notes
The study was funded by Gilead Sciences Inc.
Reference
Meyer N, et al. Revascularization Rates and Associated Costs in Patients With Stable Ischemic Heart Disease Initiating Ranolazine Versus Traditional Antianginals as Add-on Therapy. American Journal of Cardiology : 22 Feb 2019. Available from: URL: http://doi.org/10.1016/j.amjcard.2019.02.014
Rights and permissions
About this article
Cite this article
Ranolazine saves revascularisation costs in stable IHD. PharmacoEcon Outcomes News 824, 26 (2019). https://doi.org/10.1007/s40274-019-5754-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5754-4